MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
SELLAS Life Sciences Group Deferred Revenue 2011-2026 | SLS
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue SELLAS Life Sciences Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 5.6 M | - | - | - | - | - | - | - | - | 816 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.6 M | 816 K | 3.21 M |
Quarterly Deferred Revenue SELLAS Life Sciences Group
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 900 K | 5.6 M | 5.6 M | 5.6 M | 5.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 816 K | 877 K | 578 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.6 M | 578 K | 3.2 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
227 K | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
1.85 M | - | - | $ 86.2 M | USA |
 |
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | USA |
 |
argenx SE
ARGX
|
37.8 M | $ 783.17 | 2.32 % | $ 25 B |  Niderland |
 |
Applied Therapeutics
APLT
|
667 K | - | - | $ 8.42 M | USA |
 |
I-Mab
IMAB
|
563 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
124 K | - | 2.54 % | $ 160 B |  France |
 |
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
300 M | $ 91.64 | 2.25 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
187 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
33.3 K | $ 3.82 | 1.6 % | $ 9.19 B |  Australia |
 |
CymaBay Therapeutics
CBAY
|
1.69 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
165 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
339 K | $ 2.68 | 4.28 % | $ 16.8 M | USA |
 |
Avid Bioservices
CDMO
|
39.9 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
9.8 M | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 3.05 | 0.66 % | $ 6.64 B |  Israel |
 |
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M |  Canada |
 |
Cerus Corporation
CERS
|
1.27 M | $ 1.93 | 4.62 % | $ 368 M | USA |
 |
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
2.75 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
6.3 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
912 K | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
957 K | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.65 M | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
158 M | - | - | $ 867 M | Germany |
 |
Coherus BioSciences
CHRS
|
1.96 M | $ 1.73 | 3.59 % | $ 203 M | USA |